8-K Announcements
6Material company update
Feb 24, 2026·SEC
Material company update
Jan 5, 2026·SEC
Material company update
Jan 2, 2026·SEC
CeriBell, Inc.(CBLL)Earnings, Financials & Key Ratios
CBLL•NASDAQ
$20.15
$755M mkt cap·Price updated May 6, 2026
AboutCeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.Show more
- Revenue$89M+36.1%
- EBITDA-$52M-33.6%
- Net Income-$53M-32.0%
- EPS (Diluted)-1.46+56.9%
- Gross Margin87.89%+1.4%
- EBITDA Margin-57.85%+1.8%
- Operating Margin-65.57%-8.1%
- Net Margin-59.97%+3.0%
- ROE-29.21%+71.5%
- ROIC-50.04%
- Debt/Equity0.13+11.1%
- Interest Coverage-30.90-55.0%
CBLL Key Insights
CeriBell, Inc. (CBLL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 83 (top 17%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CBLL Price & Volume
CeriBell, Inc. (CBLL) stock price & volume — 10-year historical chart
Loading chart...
CBLL Growth Metrics
CeriBell, Inc. (CBLL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years50.9%
TTM36.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-32.03%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM62.21%
Return on Capital
10 Years-40.4%
5 Years-40.4%
3 Years-38.19%
Last Year-30.02%
CBLL Recent Earnings
CeriBell, Inc. (CBLL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (67%)●Beat Revenue 1/12 qtrs (17%)
Q1 2026Latest
Feb 24, 2026EPS
$0.36
Est $0.43
+16.3%
Revenue
$25M
Est $24M
+3.6%
Q4 2025
Nov 4, 2025EPS
$0.37
Est $0.43
+14.0%
Revenue
$23M
Est $24M
-5.7%
Q3 2025
Aug 5, 2025EPS
$0.38
Est $0.40
+5.0%
Revenue
$21M
Est $22M
-2.6%
Q2 2025
May 8, 2025EPS
$0.36
Est $0.43
+16.3%
Revenue
$20M
Est $21M
-0.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.36vs $0.43+16.3% | $25Mvs $24M+3.6% |
| Q4 2025 | Nov 4, 2025 | $0.37vs $0.43+14.0% | $23Mvs $24M-5.7% |
| Q3 2025 | Aug 5, 2025 | $0.38vs $0.40+5.0% | $21Mvs $22M-2.6% |
| Q2 2025 | May 8, 2025 | $0.36vs $0.43+16.3% | $20Mvs $21M-0.3% |
Based on last 12 quarters of dataView full earnings history →
CBLL Peer Comparison
CeriBell, Inc. (CBLL) competitors in Patient monitoring and wearable diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 LIVN | 3.62B | 66.26 | -14.89 | 10.74% | 7.47% | 9.13% | 0.39 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 ACLS | 5.54B | 171.00 | 45 | -17.57% | 14.33% | 11.62% | 0.04 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 PHG | 25.9B | 27.23 | 24.95 | -1.04% | 5.02% | 8.19% | 0.74 | |
 GE | 319.54B | 305.83 | 37.48 | 18.48% | 17.91% | 45.85% | 1.08 |
Compare CBLL vs Peers
CeriBell, Inc. (CBLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CBLL Income Statement
CeriBell, Inc. (CBLL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Sales/Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Revenue Growth % | - | 74.47% | 44.71% | 36.09% |
| Cost of Goods Sold | 4.43M | 7.06M | 8.69M | 10.79M |
| COGS % of Revenue | 17.09% | 15.62% | 13.28% | 12.11% |
| Gross Profit | 21.49M▲ 0% | 38.16M▲ 77.6% | 56.75M▲ 48.7% | 78.27M▲ 37.9% |
| Gross Margin % | 82.91% | 84.38% | 86.72% | 87.89% |
| Gross Profit Growth % | - | 77.57% | 48.7% | 37.93% |
| Operating Expenses | 57.51M | 68.2M | 96.46M | 136.68M |
| OpEx % of Revenue | 221.87% | 150.81% | 147.39% | 153.46% |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M | 117.53M |
| SG&A % of Revenue | 193.93% | 130.92% | 126.67% | 131.97% |
| Research & Development | 7.24M | 8.99M | 13.56M | 19.14M |
| R&D % of Revenue | 27.94% | 19.89% | 20.72% | 21.49% |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -36.02M▲ 0% | -30.04M▲ 16.6% | -39.71M▼ 32.2% | -58.4M▼ 47.1% |
| Operating Margin % | -138.96% | -66.43% | -60.68% | -65.57% |
| Operating Income Growth % | - | 16.6% | -32.18% | -47.08% |
| EBITDA | -35.52M | -29.19M | -38.57M | -51.52M |
| EBITDA Margin % | -137.04% | -64.55% | -58.93% | -57.85% |
| EBITDA Growth % | - | 17.82% | -32.11% | -33.59% |
| D&A (Non-Cash Add-back) | 497K | 847K | 1.14M | 0 |
| EBIT | -35.56M | -27.36M | -38.46M | -51.52M |
| Net Interest Income | -1.6M | -2.1M | -1.99M | -1.89M |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M | 1.89M |
| Other Income/Expense | -1.14M | 588K | -746K | 4.99M |
| Pretax Income | -37.16M▲ 0% | -29.45M▲ 20.7% | -40.45M▼ 37.4% | -53.41M▼ 32.0% |
| Pretax Margin % | -143.36% | -65.13% | -61.82% | -59.97% |
| Income Tax | 2K | 11K | 0 | 0 |
| Effective Tax Rate % | -0.01% | -0.04% | 0% | 0% |
| Net Income | -37.16M▲ 0% | -29.46M▲ 20.7% | -40.45M▼ 37.3% | -53.41M▼ 32.0% |
| Net Margin % | -143.37% | -65.15% | -61.82% | -59.97% |
| Net Income Growth % | - | 20.72% | -37.3% | -32.03% |
| Net Income (Continuing) | -37.16M | -29.46M | -40.45M | -53.41M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.59▲ 0% | -1.26▲ 20.8% | -3.39▼ 169.0% | -1.46▲ 56.9% |
| EPS Growth % | - | 20.75% | -169.05% | 56.93% |
| EPS (Basic) | -1.59 | -1.26 | -3.39 | -1.46 |
| Diluted Shares Outstanding | 23.32M | 23.32M | 11.95M | 36.54M |
| Basic Shares Outstanding | 23.32M | 23.32M | 11.95M | 36.54M |
| Dividend Payout Ratio | - | - | - | - |
CBLL Balance Sheet
CeriBell, Inc. (CBLL) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Total Current Assets | 79.8M | 51.96M | 217.27M | 186.72M |
| Cash & Short-Term Investments | 68.23M | 34.49M | 194.37M | 159.26M |
| Cash Only | 68.23M | 34.49M | 194.37M | 40.48M |
| Short-Term Investments | 0 | 0 | 0 | 118.78M |
| Accounts Receivable | 5.29M | 7.96M | 10.88M | 15.05M |
| Days Sales Outstanding | 74.56 | 64.2 | 60.67 | 61.69 |
| Inventory | 4.08M | 5.87M | 6.94M | 7.29M |
| Days Inventory Outstanding | 335.75 | 303.29 | 291.24 | 246.56 |
| Other Current Assets | 2.19M | 3.65M | 5.09M | 5.12M |
| Total Non-Current Assets | 6.66M | 6.96M | 8.14M | 9.09M |
| Property, Plant & Equipment | 3.87M | 3.74M | 4.45M | 4.33M |
| Fixed Asset Turnover | 6.69x | 12.10x | 14.72x | 20.59x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.79M | 3.22M | 3.69M | 4.76M |
| Total Assets | 86.46M▲ 0% | 58.92M▼ 31.8% | 225.41M▲ 282.6% | 195.8M▼ 13.1% |
| Asset Turnover | 0.30x | 0.77x | 0.29x | 0.45x |
| Asset Growth % | - | -31.85% | 282.56% | -13.14% |
| Total Current Liabilities | 9.86M | 21.6M | 12.99M | 19.19M |
| Accounts Payable | 423K | 732K | 1.14M | 2.84M |
| Days Payables Outstanding | 34.85 | 37.83 | 47.99 | 96.01 |
| Short-Term Debt | 2.5M | 11.83M | 0 | 1.1M |
| Deferred Revenue (Current) | 343K | 206K | 97K | 0 |
| Other Current Liabilities | 2.51M | 3.73M | 5M | 15.25M |
| Current Ratio | 8.09x | 2.41x | 16.73x | 9.73x |
| Quick Ratio | 7.68x | 2.13x | 16.19x | 9.35x |
| Cash Conversion Cycle | 375.46 | 329.66 | 303.92 | 212.24 |
| Total Non-Current Liabilities | 162.99M | 149.57M | 21.26M | 21.17M |
| Long-Term Debt | 12.72M | 0 | 19.56M | 21.17M |
| Capital Lease Obligations | 2.37M | 1.68M | 1.31M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 147.9M | 147.85M | 356K | 0 |
| Total Liabilities | 172.86M | 171.17M | 34.25M | 21.28M |
| Total Debt | 18.22M | 14.2M | 21.96M | 22.28M |
| Net Debt | -50.02M | -20.29M | -172.41M | -18.2M |
| Debt / Equity | - | - | 0.11x | 0.13x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -22.47x | -14.32x | -19.93x | -30.90x |
| Total Equity | -86.4M▲ 0% | -112.25M▼ 29.9% | 191.16M▲ 270.3% | 174.53M▼ 8.7% |
| Equity Growth % | - | -29.92% | 270.3% | -8.7% |
| Book Value per Share | -3.70 | -4.81 | 16.00 | 4.78 |
| Total Shareholders' Equity | -86.4M | -112.25M | 191.16M | 155.34M |
| Common Stock | 5K | 5K | 36K | 0 |
| Retained Earnings | -97.03M | -126.49M | -166.94M | -220.36M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 159K |
| Minority Interest | 0 | 0 | 0 | 0 |
CBLL Cash Flow Statement
CeriBell, Inc. (CBLL) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Cash from Operations | -32M | -29.16M | -35.04M | -40.81M |
| Operating CF Margin % | -123.45% | -64.48% | -53.55% | -45.82% |
| Operating CF Growth % | - | 8.88% | -20.18% | -16.45% |
| Net Income | -37.16M | -29.46M | -40.45M | -53.41M |
| Depreciation & Amortization | 497K | 847K | 1.14M | -670K |
| Stock-Based Compensation | 7.93M | 2.68M | 5.41M | 12.22M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 621K | 477K | 2.03M | 1.05M |
| Working Capital Changes | -3.88M | -3.7M | -3.17M | 0 |
| Change in Receivables | -3.96M | -3.43M | -3.51M | -4.17M |
| Change in Inventory | -1.9M | -1.79M | -1.07M | -351K |
| Change in Payables | 124K | 309K | 250K | 1.75M |
| Cash from Investing | -1.4M | -1.76M | -1.6M | -118.14M |
| Capital Expenditures | -516K | -983K | -1.34M | -767K |
| CapEx % of Revenue | 1.99% | 2.17% | 2.05% | 0.86% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | -883K | -780K | -258K | -755K |
| Cash from Financing | 49.8M | -2.82M | 196.52M | 5.05M |
| Debt Issued (Net) | -39K | -3.75M | 7.91M | 0 |
| Equity Issued (Net) | 1000K | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | 154K | 932K | -304K | 5.05M |
| Net Change in Cash | 16.4M▲ 0% | -33.74M▼ 305.7% | 159.88M▲ 573.8% | -153.89M▼ 196.3% |
| Free Cash Flow | -32.52M▲ 0% | -30.14M▲ 7.3% | -36.38M▼ 20.7% | -41.58M▼ 14.3% |
| FCF Margin % | -125.45% | -66.65% | -55.59% | -46.68% |
| FCF Growth % | - | 7.31% | -20.71% | -14.27% |
| FCF per Share | -1.39 | -1.29 | -3.04 | -1.14 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.99x | 0.87x | 0.76x |
| Interest Paid | 1.63M | 1.73M | 1.95M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
CBLL Key Ratios
CeriBell, Inc. (CBLL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -102.53% | -29.21% |
| Return on Invested Capital (ROIC) | - | - | - | -50.04% |
| Gross Margin | 82.91% | 84.38% | 86.72% | 87.89% |
| Net Margin | -143.37% | -65.15% | -61.82% | -59.97% |
| Debt / Equity | - | - | 0.11x | 0.13x |
| Interest Coverage | -22.47x | -14.32x | -19.93x | -30.90x |
| FCF Conversion | 0.86x | 0.99x | 0.87x | 0.76x |
| Revenue Growth | - | 74.47% | 44.71% | 36.09% |
CBLL SEC Filings & Documents
CeriBell, Inc. (CBLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
CBLL Frequently Asked Questions
CeriBell, Inc. (CBLL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CeriBell, Inc. (CBLL) reported $89.1M in revenue for fiscal year 2025. This represents a 244% increase from $25.9M in 2022.
CeriBell, Inc. (CBLL) grew revenue by 36.1% over the past year. This is strong growth.
CeriBell, Inc. (CBLL) reported a net loss of $53.4M for fiscal year 2025.
Dividend & Returns
CeriBell, Inc. (CBLL) has a return on equity (ROE) of -29.2%. Negative ROE indicates the company is unprofitable.
CeriBell, Inc. (CBLL) had negative free cash flow of $41.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More CBLL
CeriBell, Inc. (CBLL) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates